Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 4;10:13079. doi: 10.1038/s41598-020-70157-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Kaplan–Meier curves for overall survival of NSCLC assessed using the log-rank test. (A) High expression of miR-4634 in lung SCC, ADC, and non-CLT. Significant differences were observed between the groups, statistically evaluated by chi-square test (***P < 0.001). (B) The high expression of miR-4634 was more frequent in primary tumors than metastasis tissue of NSCLC (P = 0.043). (C) Low expression of miR-4634 was significantly associated with short survival time of patients with NSCLC (P = 0.012). (D) Patients with LNM were more likely to have poor overall survival compared with patients without LNM (P < 0.001). (E) Patients with poorly differentiated cancer were more likely to have poorer overall survival than patients with well/moderately differentiated tumors (P = 0.010). (F) Patients with clinical stage I and II disease were more likely to have better overall survival than patients with clinical stage III tumors (P < 0.001). The survival curve graphs were performed using SPSS V19.0 (https://spss.en.softonic.com/).